Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Urology
Published in: World Journal of Urology 1/2010

01-02-2010 | Original Article

Identification of urine PLK2 as a marker of bladder tumors by proteomic analysis

Authors: Lia-Beng Tan, Kow-Tong Chen, Yu-Chang Yuan, Pao-Chi Liao, How-Ran Guo

Published in: World Journal of Urology | Issue 1/2010

Login to get access

Abstract

Objective

To determine the patterns of urinary proteins in bladder cancer subjects using pooled urine from 27 bladder cancer patients.

Methods

The urine matrix was removed by acetonitrile precipitation followed by molecular weight cutoff. High performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (HPLC–ESI-MS/MS) was used to analyze the urinary proteome. The candidate protein was validated by western blot.

Results

A total of 146 urinary proteins were identified. The protein list was screened using bioinformatic tools, and 11 cancer-related urinary proteins were found to be potential tumor markers for bladder cancer. However, only PLK2 was identified with high confidence. This candidate protein was validated by western blot using urine samples from 14 normal subjects and 10 bladder cancer patients. Statistically significant correlations were detected between PLK2 expression and bladder transitional cell carcinoma (TCC) (P < 0.05). Urinary PLK2 had a sensitivity of 80% at a specificity of 64% for bladder TCC in the samples tested.

Conclusions

Our results demonstrate overexpression of PLK2 in bladder carcinomas, suggesting a possible role of PLK2 in the pathogenesis of bladder carcinomas. However, the small cohort, preliminary results, and lack of subgroup analysis (such as carcinoma in situ, high grade, and stage) in this study prevent us from drawing definitive conclusions about the diagnostic value of PLK2 in these patients. Further studies directed toward a multitude of possible carcinogenic mechanisms of PLK2 in bladder cancer are warranted.
Literature
1.
Vlahou H, Schellhammer PF, Mendrinos S et al (2001) Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 158:1491–1502PubMed
2.
Sarosdy MF, deVere White RW, Soloway MS (1995) Results of a multicenter trial using the BTA test to monitor for and diagnosis recurrent bladder cancer. J Urol 154:379–384CrossRefPubMed
3.
Sharms S, Zipper CD, Pandrangi L (1999) Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA test. J Urol 162:53–57CrossRef
4.
Greence FL, Page DL, Fleming ID et al (eds) (2002) American Joint Committee on Cancer Staging manual, 6th edn. Springer, Philadelphia
5.
World Health Organization (1988) International histological classification of tumors, 2nd edn. World Health Organization, Geneva, 1969–1981, Springer, Berlin
6.
Tan LB, Chen KT, Tyan YC, Liao PC, Guo HR (2008) Proteomic analysis for human urinary proteins associated with arsenic intoxication. Proteomic Clin Appl 2:1087–1098CrossRef
7.
Bradford MM (1976) A rapid and sensitive method for the quantitation of protein. Anal Biochem 72:248–254CrossRefPubMed
8.
Washburn MP, Wolters DA, Yates JR (2001) Large-scale analysis of the yeast proteome by multidimensional technology. Nat Biotechnol 19:242–247CrossRefPubMed
9.
Wang GY, Lu CQ, Zhang RM, Hu XH, Luo ZW (2008) The E-cadherin gene polymorphism 160C→A and cancer risk: a HuGE review and meta-analysis of 26 case–control studies. Am J Epidemiol 167:7–14CrossRefPubMed
10.
Kunzli BM, Berberat PO, Zhu ZW et al (2002) Influences of the lysosomal associated membrane proteins (Lamp-1, Lamp-2) and Mac-2 binding protein (Mac-2-BP) on the prognosis of pancreatic carcinoma. Cancer 94:228–239CrossRefPubMed
11.
Saitoh O, Wang WC, Lotan R, Fukuda M (1992) Differential glycosylation and cell surface expression of lysosomal membrane glycoproteins in sublines of a human colon cancer exhibiting distinct metastatic potentials. J Biol Chem 267:5700–5711PubMed
12.
Ang C, Chambers AF, Tuck AB, Winquist E, Izawa JI (2005) Plasma osteopontin levels are predictive of disease stage in patients with transitional cell carcinoma of the bladder. BJU Int 96:803–805CrossRefPubMed
13.
Deepak AG, Chen T, Irby R et al (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94:513–516
14.
Tolson JP, Flad T, Gnau V et al (2006) Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics 6:697–708CrossRefPubMed
15.
El-Rifai W, Moskaluk CA, Abdrabbo MK et al (2002) Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 62:6823–6826PubMed
16.
Yoon SY, Lee Y, Kim JH et al (2005) Over-expression of human UREB1 in colorectal cancer: HECT domain of human UREB1 inhibits the activity of tumor suppressor p53 protein. Biochem Biophys Res Commun 326:7–17CrossRefPubMed
17.
Wang Y, Han KJ, Pang XW et al (2002) Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J Immunol 169:1102–1109PubMed
18.
Rudman D, Chawla RK, Wadsworth AD, Nixon DW, Schwartz M (1977) A system of cancer-related urinary glycoproteins: biochemical properties and clinical applications. Trans Assoc Am Physicians 90:286–299PubMed
19.
Chawla RK, Lawson DH, Ahmad M, Travis J (1992) Cancer-related urinary proteinase inhibitor, EDC1: a new method for its isolation and evidence for multiple forms. J Cell Biochem 50:227–236CrossRefPubMed
20.
Syed N, Smith P, Sullivan A et al (2006) Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood 107:250–256CrossRefPubMed
21.
Ylagan LR, Scholes J, Demopoulos R (2000) CD 44: a marker of squamous differentiation in adenosquamous neoplasms. Arch Pathol Lab Med 124:212–215PubMed
22.
Miyake H, Hara I, Kamidono S, Eto H (2004) Multifocal transitional cell carcinoma of the bladder and upper urinary tract: molecular screening of clonal origin by characterizing CD44 alternative splicing patterns. J Urol 172:1127–1129CrossRefPubMed
23.
Koochekpour S, Zhuang YJ, Beroukhim R et al (2005) Amplification and overexpression of prosaposin in prostate cancer. Genes Chromosomes Cancer 44:351–364CrossRefPubMed
24.
Mukoyama Y, Zhou S, Miyachi Y, Matsuyoshi N (2005) T-cadherin negatively regulates the proliferation of cutaneous squamous carcinoma cells. J Invest Dermatol 124:833–838CrossRefPubMed
25.
Halachmi S, Linn JF, Amiel GE, Moskovitz B, Nativ O (1998) Urine cytology, tumour markers and bladder cancer. Brit J Urol 82:647–654PubMed
26.
Sphar CS, Davis MT, McGinley MD et al (2001) Towards defining the urinary proteome using liquid chromatography–tandem mass spectrometry. I. Profiling an unfractionated tryptic digest. Proteomics 1:93–107CrossRef
27.
D’Assoro AB, Lingle L, Salisbury JL (2000) Centrosome amplification and the development of cancer. Oncogene 21:6146–6153CrossRef
28.
29.
Nigg E (2000) Centrosome aberrations: cause or consequence of cancer progression? Nat Rev Cancer 2:815–825CrossRef
30.
Yamamoto Y, Matsuyama H, Kawauchi S et al (2006) Overexpression of Polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer. Oncology 70:231–237CrossRefPubMed
Metadata
Title
Identification of urine PLK2 as a marker of bladder tumors by proteomic analysis
Authors
Lia-Beng Tan
Kow-Tong Chen
Yu-Chang Yuan
Pao-Chi Liao
How-Ran Guo
Publication date
01-02-2010
Publisher
Springer-Verlag
Published in
World Journal of Urology / Issue 1/2010
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-009-0432-y

Other articles of this Issue 1/2010

World Journal of Urology 1/2010 Go to the issue

Topic Paper

Thulium laser enucleation of the prostate (ThuLEP): transurethral anatomical prostatectomy with laser support. Introduction of a novel technique for the treatment of benign prostatic obstruction

Topic Paper

Current status of 5α-reductase inhibitors in the management of lower urinary tract symptoms and BPH

Original Article

Factors predicting inguinal node metastasis in squamous cell cancer of penis

Original Article

Urinary collecting system invasion reflects adverse long-term outcome and is associated with simultaneous metastatic spread at the time of surgery and with multilocular dissemination during postsurgical follow-up in renal cell cancer

Original Article

The difference in oxidative stress of the blood between using 5% glucose water and distilled water as the irrigant for BPH patients undergoing transurethral resection of the prostate

Original Article

Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction